

JOHNSON & JOHNSON
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. and E.U. DEVELOPMENT OR REGISTRATION
As of October 19, 2010*

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
<u>Central Nervous System</u>	INVEGA (paliperidone ER OROS)	Pediatric indication - adolescent schizophrenia Schizoaffective disorder	Filed 10/10 Approved 7/09	Phase III Positive CHMP Opinion 9/10
	INVEGA SUSTENNA (paliperidone palmitate IM long acting injectable)	Schizophrenia (1)	Approved 7/09	Filed 12/09
	bapineuzumab	Alzheimer's disease (7)	Phase III	
	CONCERTA (OROS methylphenidate)	Adult attention deficit hyperactivity disorder	Approved 6/08	Filed 3/10
<u>Gastrointestinal</u>	REMICADE (infliximab)	Pediatric Ulcerative Colitis	Phase III	
<u>Immunology</u>	STELARA (ustekinumab)	Psoriatic Arthritis	Phase III	Phase III
	SIMPONI (golimumab)	Rheumatoid Arthritis (IV) Structural Damage (RA) Structural Damage (PsA) Ulcerative Colitis	Phase III Filed 9/10 Phase III Phase III	Phase III (3) Filed 3/10 (3) Phase III (3) Phase III (3)
<u>Hematology</u>	PROCRIT (epoetin alfa)	Chronic Renal Function - extended dosing (6)	Filed 3/10	Filed 4/10
<u>Infectious Disease</u>	DORIBAX (doripenem)	Nosocomial Pneumonia (6)	FDA Complete Response letter 8/08 FDA Second Complete Response 10/10	Approved 7/08
<u>Oncology</u>	VELCADE (bortezomib)	Non-Hodgkin's Lymphoma (6) Mantle Cell Lymphoma 1st line (6) Subcutaneous formulation		Phase III Phase III Phase III
	YONDELIS (trabectedin)	Relapsed Ovarian Cancer (6)	FDA Complete Response letter 9/09	
	abiraterone acetate	Prostate cancer (chemo-refractory and chemo naïve)	Phase III	Phase III
	DACOGEN (decitabine) for Injection	Acute Myeloid Leukemia (6)		Phase III
<u>Anti-Viral</u>	telaprevir	Chronic hepatitis C virus (HCV) infection		Phase III (6)
	TMC278 (rilpivirine)	NNRTI HIV/AIDS treatment-naïve patients	Filed 7/10	Filed 9/10
<u>Pain Management</u>	NUCYNTA ER (tapentadol)	Moderate to severe chronic pain (Extended Release formulation) (6) Diabetic peripheral neuropathy (Extended Release formulation) (6)	FDA Complete Response letter 10/10 Phase III	
<u>Cardiovascular/Metabolism</u>	rivaroxaban	VTE Prophylaxis (Prevention of venous thromboembolism in hip and knee replacement surgery) (6) Stroke prevention in atrial fibrillation (6) VTE treatment (6) Acute Coronary Syndrome (6) Medically III (6)	FDA Complete Response letter 5/09 Phase III Phase III Phase III Phase III	
	canagliflozin	Type 2 diabetes (6)	Phase III	Phase III
	GAD65 antigen-based therapy	Type 1 diabetes (6)	Phase III	Phase III
<u>Sexual Health</u>	PRILIGY (dapoxetine)	Premature ejaculation (6)	FDA non-approvable letter 10/05	Approved 2/09 (4)

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(1) Collaboration with Elan Corporation, plc

(2) Collaboration with Alkermes, Inc.. EU filing submitted as Type II Variations

(3) EU rights are currently under dispute in arbitration as a result of the acquisition of Schering Plough by Merck

(4) Select EU countries

(6) Doribax™ developed in collaboration with Shionogi & Co., canagliflozin licensed from Mitsubishi Tanabe Pharma Corporation; Procrit®/Eprex® licensed from Amgen Inc.,

Velcade® developed in collaboration with Millennium Pharmaceuticals, The Takeda Oncology Company, Yondelis® developed in collaboration with PharmaMar, Dacogen® developed in collaboration with Eisai Corporation of North America, Nucynta™ co-developed with Grunenthal GMBH, rivaroxaban co-developed with Bayer HealthCare, Priligy® developed in collaboration with Furiex Pharmaceuticals, telaprevir developed in collaboration with Vertex Pharmaceuticals Incorporated, GAD65 antigen-based therapy licensed from Diamyd Medical AB.

(7) Acquired from Elan Pharmaceuticals plc and being developed in collaboration with Pfizer

Johnson & Johnson

Pharmaceutical Pipeline - Recent Approvals/Potential Filings*

Selective Highlights as of 10/19/2010

Approved 2009	In Registration	Planned Filings 2010	Planned Filings 2011-2013
<p>INVEGA® SUSTENNA™ (paliperidone palmitate) <i>Neuroscience</i></p>	<p>Rivaroxaban <i>Cardiovascular & Metabolism</i></p>	<p>Abiraterone Acetate <i>Oncology</i></p>	<p>Fulranumab (Anti-Nerve Growth Factor) <i>Neuroscience</i></p>
<p>PRILIGY™ (E.U.) (dapoxetine) <i>Sexual Health</i></p>	<p>TMC 278 (rilpivirine) <i>Infectious Disease</i></p>	<p>Telaprevir (E.U.) <i>Infectious Disease</i></p>	<p>Bapineuzumab IV <i>Neuroscience</i></p>
<p>SIMPONI™ (golimumab) <i>Immunology</i></p>	<p>YONDELIS™ (trabectedin) <i>Oncology</i></p>		<p>Canagliflozin <i>Cardiovascular & Metabolism</i></p>
<p>STELARA™ (ustekinumab) <i>Immunology</i></p>			<p>DACOGEN™ (E.U.) (decitabine) <i>Oncology</i></p>
			<p>Siltuximab (CNTO 328) <i>Oncology</i></p>
			<p>CNTO 136 <i>Immunology</i></p>
			<p>TMC 207 <i>Infectious Disease</i></p>
			<p>TMC 435 <i>Infectious Disease</i></p>

*Filings/approvals assumed to be in U.S. unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

Yondelis® developed in collaboration with PharmaMar, Dacogen® developed in collaboration with Eisai Corporation of North America, Rivaroxaban co-developed with Bayer HealthCare, Priligy® developed in collaboration with Furiex Pharmaceuticals, Telaprevir developed in collaboration with Vertex Pharmaceuticals Incorporated; Fulranumab licensed from Amgen, Inc.; Canagliflozin developed in collaboration with Mitsubishi-Tanabe Pharmaceutical Corporation; TMC435 developed in collaboration with Medivir AB. Bapineuzumab being developed in collaboration with Pfizer.

MD&D Pipeline Highlights – Cordis, DePuy, Diabetes Care

Pending

Cordis

NEVO™
Coronary Stent (CE Mark)

EXOSEAL™
VCD (PMA)

CARTO® 3
Navigation Technology (China)

THERMOCOOL® SF
Irrigated Catheter (PMA)

CYPHER®
Coronary Stent 4.0 (PMA)

CYPHER® Xtend
Extended Dating (PMA Supp)

THERMOCOOL® SMARTTouch™
Contact Force Catheter (CE Mark)

DePuy

AOX Poly for Sigma® and LCS®
CoMplete™

Acetabular Hip System

RECLAIM™ Hip Revision

Shoulder Fracture Platform

MEDSTREAM™*
Programmable Pump

TLIF Cage

VIPER® LX

Diabetes Care

OneTouch® Verio™ Blood Glucose System
Version 1

OneTouch® Verio™ Blood Glucose System
Version 2 (CE Mark)

2009-2010

Approved/Cleared

Cordis

CYPHER® Coronary Stent 2.25 (PMA Supp)

EXOSEAL™ VCD (CE Mark)

CARTO® 3
Navigation Technology (510(k), CE Mark, and Japan)

CARTO® 3
Diagnostics Catheter Portfolio (510(k) & CE Mark)

NAVISTAR® THERMOCOOL®
Afib Indication (PMA)

THERMOCOOL® SF
Irrigated Catheter (CE Mark)

PRESILLION™ Plus
Bare Metal Stent (CE Mark)

CYPHER SELECT® Plus Stent (Japan)

CARTO® Xpress
Navigation Technology (510(k) & CE Mark)

DePuy

ASPHERE™*
Contoured Metal Heads

GRIPTION™ TF (TIFOAM)* Hip and Knee

Sigma® CR150* Mobile Bearing

A.L.P.S. System Modules*
(Anatomic Fibula, Anatomic Elbow, Proximal Tibia)

AFFIXUS™ Hip Fracture Nail*

CONFIDENCE Spinal Cement System™ LX

COUGAR® LS Lateral Cage

EXPEDIUM® LX

ScoliScore™ AIS Prognostic Test

GRYPHON™ BR ANCHOR

VapriVue™ & Coolpulse™ 90

NEXTRA® System (CE Mark)

ORBIT GALAXY™ Detachable Embolic Coil*

Diabetes Care

ONETOUCH® Ping™ (Canada)

OneTouch® Verio™ Blood Glucose System
Version 1 (CE Mark)

2010

Planned Submissions

Cordis

CARTO® 3 V2 Navigation Technology
(510(k) & CE Mark)

PTA Balloons Next Generation
(510(k) & CE Mark)

THERMOCOOL® SF Irrigated Catheter
(Japan)

EXOSEAL™
VCD (Japan)

DePuy

SIGMA® PS150 (CE Mark)

Diabetes Care

Integrated Continuous Glucose
Monitor/Insulin Pump
(PMA & CE Mark)

Select Next Generation (CE mark)

2011

Planned Submissions

Cordis

CARTO® 3 V3
Navigation Technology (510(k) & CE Mark)

INCRAFT™
AAA Stent Graft (CE Mark)

PRESILLION™ Plus
Bare Metal Stent (PMA)

S.M.A.R.T.®
Stent for SFA (PMA Supp)

PTCA Balloon
Next Generation (PMA & CE Mark)

DePuy

Bone Preserving Hip Stem

New Poly Hip Bearings

Next Generation Knee System

DVR Express

Next Generation DVR® Wrist Plate*

Platelet Rich Plasma System

WW Screw

Diabetes Care

Next Generation ONETOUCH® Ping (US & Canada)

Next Generation POC Testing System
(Emerging Markets)

OneTouch® Verio™ Blood Glucose System
Version 2 (US)

2012



Planned Submissions

Cordis

NEVO™
Coronary Stent (PMA & Japan)

THERMOCOOL® SMARTTouch®
Contact Force Catheter (PMA)

INCRAFT™
AAA Stent Graft (PMA & Japan)

Circular Ablation
(PMA & CE Mark)

Next Gen NEVO™
Coronary Stent (PMA & CE Mark)

DePuy

CAIS Cartilage Regeneration

DeltaMotion® Hip System*

Hip Bearings

Hip Resurfacing System

Next Generation Hip System

Next Generation Shoulder

Diabetes Care

OneTouch® Verio™ Blood Glucose System
Version 3 (CE mark & US)

* U.S. submission only.

Selective Highlights as of 10/19/10. Filings/approvals assumed to be in U.S. unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information

MD&D Pipeline Highlights – Ethicon, EES, OCD, Vision Care

Pending

Ethicon

SURGIFLO® with Integrated Thrombin Kit (EU)
DERMABOND® Topical Skin Adhesive
New Formulation

OCD

ORTHO VERSEIA® Pipettor Assays
New VITROS® Assay:
- Hepatitis B e-antigen
and antibody

2009-2010

Approved/Cleared

Ethicon

PROCEED™ Ventral Patch (EU)
PDS™ Plus Antibacterial (polydioxanone)
Suture (EU)
PDS™ Flexible Plates (U.S. & EU)
SURGIFLO® with Integrated Thrombin Kit
NUVANCE™ Facial Rejuvenation System
(EU)
PREVELLE™ Lift Dermal Filler (EU)
ETHICON SECURESTRAP™ 5mm Strap
Fixation Device
ETHICON PHYSIOMESH™ Flexible
Composite Mesh
PRINEO Skin Closure System
DERMABOND® Topical Skin Adhesive
New Formulation
MENTOR® – Sensitive Anatomical Gel
(EU)
GYNECARE MORCELLEX™ Re-Launch
GYNECARE PROSIMA™ Pelvic Floor
Repair System
GYNECARE TVT EXACT™ Continen-
ce System
ETHICON OMNEX™ Surgical Sealant
GYNECARE TVT ABBREVO™
Continen- ce System

2009-2010

Approved/Cleared Continued

Ethicon Endo-Surgery

Echelon Flex™ 60mm Stapler
ENSEAL® Advanced Bipolar Shears
Ethicon Endo-Surgery LINEAR CUTTER and
Selectable Cartridges/Reloads
Curved & Straight Intraluminal Staplers
HARMONIC® FOCUS Long Curved Shears
ECHELON FLEX™ 45mm Stapler
HARMONIC® ACE Curved Shears with
Ergo Handle (ACE45E)
SEDASYS® System (Canada & EU)
HARMONIC® SYNERGY Combination Hook Blade
Echelon™ 60mm Thin Tissue Cartridge

OCD

VITROS® 5600 System*
VITROS® 3600 System*
120 VITROS® Assays
CELLEX™ Photopheresis System
ORTHO VERSEIA® Pipettor

Vision Care

1-DAY ACUVUE® MOIST® for ASTIGMATISM
1-DAY ACUVUE® TruEye™

2010

Planned Submissions

Ethicon

EVERPOINT™ Cardiovascular Needles
Fibrin Pad (BLA)
GYNECARE V-Support Treatment Project
Acclarent™ – CYCLOPS™ Multi-Angle Endoscope
Acclarent™ – RELIEVA LUMA® II Catheter

Ethicon Endo-Surgery

ENSEAL® Curved Open Shears
HARMONIC®/ENSEAL® Combo Generator
Endopath® XCEL™ 5mm with OPTIVIEW™
Technology
STERRAD® Solution Expansion
GLOSAIR™ Area Decontamination Solution

OCD

New VITROS® Assay:
- Intact parathyroid hormone

2011

Planned Submissions

Ethicon

Fibrin Pad (EU)
VICRYL RAPIDE™ Plus Suture
GYNECARE SUI Sling Next Generation
PurTox™ Highly Purified Botulinum Neurotoxin

Ethicon Endo-Surgery

ECHELON™ Next Gen Device
ENSEAL® Next Gen Bipolar Lap Shears
HARMONIC® Next Gen Ortho
HARMONIC® Next Gen Platform
STERRAD® Solution Expansion
Next Gen High-Level Disinfection

OCD

New VITROS® Assays
- HIV Combo²
- Prostate-specific antigen² (PSA and Free PSA)
- Syphilis
- VITROS® 4600 System¹

2012

Planned Submissions

Ethicon

ETHICON Next Generation Wound Closure
Project
Mentor® – Becker Round Adjustable Gel
GYNECARE Next Generation
Pelvic Floor Repair Project

Ethicon Endo-Surgery

Metabolics
Next Gen MIS
Next Gen Energy Solutions
Next Gen Stapling
STERRAD® Solution Expansion
Next Gen High-Level Disinfection

OCD

New VITROS® Assay: Vitamin D
VITROS® 5300 System
Transfusion Medicine Platform
CELLEX™ System: Crohn's Disease
and Graft-versus-host disease
Advanced Cellular Diagnostics
Molecular Diagnostics
Next Generation:
Circulating Tumor Cell Platform

Vision Care

Anti-allergy drug with a contact lens

Selective Highlights as of 10/19/10. Filings/approvals assumed to be in U.S. unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information

¹ Regulatory submission based on FDA filing for current platforms

² PMA

* VITROS® 5600 System approved 10/08; VITROS® 3600 System approved 12/08; Both launched 2009